Association Between Coronary and Peripheral Vascular Injury in Heart Failure Patients With Preserved Ejection Fraction. (COROVASC)
Heart Failure With Preserved Ejection Fraction
About this trial
This is an interventional diagnostic trial for Heart Failure With Preserved Ejection Fraction focused on measuring Ultrahigh-frequency ultrasound, Heart Failure with Preserved Ejection Fraction, Microcirculation, Arterial remodeling, Small arteries, Ischemia
Eligibility Criteria
Inclusion Criteria : Group 1 : Patients who are ≥ 18 years old Heart failure with preserved ejection fraction (LVEF ≥ 50%) B-type natriuretic peptide (BNP) > 35 pg/mL at inclusion Coronary macrovascular disease (significant coronary stenosis, which may have required revascularization by stenting or coronary bypass surgery). Group 2 : Patients who are ≥ 18 years old Heart failure with preserved ejection fraction (LVEF ≥ 50%) B-type natriuretic peptide (BNP) > 35 pg/mL at screening Absence of coronary macrovascular disease (no significant coronary atheroma (< 30%) or history of stenting or coronary bypass surgery). Non-inclusion Criteria : Group 1 and group 2 : Patients under legal protection Patients not affiliated to a Social Security system Patient under State Medical Help (France - AME) Pregnancy or breastfeeding Refusal or inability to sign consent Known and treated retinal vasculopathy Severe or non-stabilized hypertension (BP > 180/100 mmHg at screening) History of LVEF < 40%.
Sites / Locations
- Hôpital européen Georges Pompidou - AP-HP
Arms of the Study
Arm 1
Arm 2
Other
Other
Heart Failure Preserved Ejection Fraction with coronary disease
Heart Failure Preserved Ejection Fraction without coronary disease